Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.53/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.53/Share

Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Strategic Update

March 24, 2016 7:30 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a preclinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a strategic update and review of recent business highlights.

We continue to seek to create value by advancing our internal development programs and remain on target to make our planned submission of an investigational new drug application for EBI-031 during the second quarter of 2016, said Abbie Celniker, Ph.D., President and Chief Executive... More